CCTG has opened the anticipated international brain cancer study CCTG CE9 (LUMOS2) - joining forces with the Australian Cooperative Trials Group for Neuro-Oncology (COGNO) to make enrollment accessible to Canadian patients.
Radiotherapy to Block (CURB2) Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
STRIDE (durvalumab + tremelimumab) with Lenvatinib vs STRIDE Alone in Patients with Unresectable Hepatocellular Carcinoma (SLIDE-HCC)
LND101 for Fecal Microbiota Transplantation in Combination with Immune Checkpoint Blockade in Patients with Advanced Melanoma
Addition of Docetaxel to Androgen Receptor Pathway Inhibitors in Patients with Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response (TRIPLE-SWITCH)
The CCTG ES3 NEEDS international esophageal cancer clinical trial is now opened in Canada. The study is investigating whether delaying surgery for patients with squamous cell carcinoma of the esophagus is as good as the current treatment.
Eradicating MRD in Patients with AML prior to Stem Cell Transplant (ERASE)
VIGOR: Vorasidenib as Maintenance Treatment after First-line Chemoradiotherapy in IDH-mutant Grade 2 or 3 Astrocytoma
Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Advanced, Colorectal Adenocarcinoma: The BATTMAN Trial
Delayed Reduced Volume and Dose Elective Ratiotherapy (REVERT) in Patients with HNSCC
CALMS: Combination Therapy with Luspatercept in Lower Risk MDS CTEP approval: 2024AUG27 (date of US Steering Committee Evaluation)
Dr. Aly-Khan A. Lalani, B.Sc (Hons), MD, FRCPC, has been awarded the 2022 CCTG Dr. Elizabeth Eisenhauer Early Drug Development Young Investigator Award recognizing his work as a new investigator who has contributed significantly to the conduct of an IND trials.
The Allan Blair Cancer Centre IND234 trial team has been awarded the 2022 CCTG IND Team Award for performance in trial accrual, local activation timelines, and compliance metrics, team performance.
CCTG is currently seeking volunteer Patient Representatives for the Brain Disease Site Committee (brain cancer) as well as for the Head and Neck Disease Site Committee (cancer inside the nose, throat or mouth). Patient Representatives participate in all aspects of disease site committee activities and are members of the CCTG Patient Representative Committee.
The Canadian Cancer Society (CCS) has renewed its support of the Canadian Cancer Trials Group (CCTG) with a five-year 30-million-dollar commitment to the national research network. The grant renewal represents a continuation of CCS’s largest research investment, which began in 1980 when they helped create the Canadian academic research group.